Significant increase of cytotoxic IFN-γ and dramatic reduce of suppressive TGF-β1 suggested that inCVAX treatment effectively activates immunity in HCC-bearing mice, possibly a Th1 response. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.